Search

Your search keyword '"Luis Jimenez-Jimenez"' showing total 3 results
Start Over Author "Luis Jimenez-Jimenez" Search Limiters Full Text
3 results on '"Luis Jimenez-Jimenez"'

1. Influence of IL28B polymorphisms on response to a lower-than-standard dose peg-IFN-α 2a for genotype 3 chronic hepatitis C in HIV-coinfected patients.

Author

Luis F López-Cortés, Rosa Ruiz-Valderas, Luis Jimenez-Jimenez, María F González-Escribano, Almudena Torres-Cornejo, Rosario Mata, Antonio Rivero, Juan A Pineda, Manuel Marquez-Solero, Pompeyo Viciana, and Grupo para el Estudio de las Hepatitis Víricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas

Subjects
Medicine, Science
Abstract

BACKGROUND:Data on which to base definitive recommendations on the doses and duration of therapy for genotype 3 HCV/HIV-coinfected patients are scarce. We evaluated the efficacy of a lower peginterferon-α 2a dose and a shorter duration of therapy than the current standard of care in genotype 3 HCV/HIV-coinfected patients. METHODS AND FINDINGS:Pilot, open-label, single arm clinical trial which involved 58 Caucasian HCV/HIV-coinfected patients who received weekly 135 µg peginterferon-α 2a plus ribavirin 400 mg twice daily during 20 weeks after attaining undetectable viremia. The relationships between baseline patient-related variables, including IL28B genotype, plasma HCV-RNA, ribavirin dose/kg, peginterferon-α 2a and ribavirin levels with virological responses were analyzed. Only 4 patients showed lack of response and 5 patients dropped out due to adverse events related to the study medication. Overall, sustained virologic response (SVR) rates were 58.3% by intention-to-treat and 71.4% by per protocol analysis, respectively. Among patients with rapid virologic response (RVR), SVR and relapses rates were 92.6% and 7.4%, respectively. No relationships were observed between viral responses and ribavirin dose/kg, peginterferon-α 2a concentrations, ribavirin levels or rs129679860 genotype. CONCLUSIONS:Weekly 135 µg pegIFN-α 2a could be as effective as the standard 180 µg dose, with a very low incidence of severe adverse events. A 24-week treatment duration appears to be appropriate in patients achieving RVR, but extending treatment up to just 20 weeks beyond negativization of viremia is associated with a high relapse rate in those patients not achieving RVR. There was no influence of IL28B genotype on the virological responses. TRIAL REGISTRATION:ClinicalTrials.gov NCT00553930.

Published
2012
Full Text
View/download PDF

2. Maternal Body-Mass Index and Cord Blood Circulating Endothelial Colony-Forming Cells

Author

Ruei-Zeng Lin, Juan M. Melero-Martin, Antonio J. Vallejo-Vaz, Juan Manuel Praena-Fernández, José Bernal-Bermejo, Jose Villar, Luis Jimenez-Jimenez, María Miranda, Rafael Moreno-Luna, Pablo Stiefel, and Rocío Muñoz-Hernández

Subjects
Adult, Male, Physiology, Umbilical cord, Article, Body Mass Index, chemistry.chemical_compound, Pregnancy, Medicine, Humans, Mass index, Progenitor cell, Cells, Cultured, business.industry, Stem Cells, Infant, Newborn, Endothelial Cells, medicine.disease, Fetal Blood, Vascular endothelial growth factor, medicine.anatomical_structure, chemistry, Cord blood, Pediatrics, Perinatology and Child Health, Immunology, Premature Birth, Female, Stem cell, business, Body mass index
Abstract

Endothelial colony-forming cells (ECFCs) are a subset of circulating endothelial progenitor cells that are particularly abundant in umbilical cord blood. We sought to determine whether ECFC abundance in cord blood is associated with maternal body-mass index (BMI) in nonpathologic pregnancies.We measured the level of ECFCs in the cord blood of neonates (n = 27) born from non-obese healthy mothers with nonpathologic pregnancies and examined whether ECFC abundance correlated with maternal BMI. We also examined the effect of maternal BMI on ECFC phenotype and function using angiogenic and vasculogenic assays.We observed variation in ECFC abundance among subjects and found a positive correlation between prepregnancy maternal BMI and ECFC content (r = 0.51, P = .007), which was independent of other obstetric factors. Despite this variation, ECFC phenotype and functionality were deemed normal and highly similar between subjects with maternal BMI25 kg/m(2) and BMI between 25-30 kg/m(2), including the ability to form vascular networks in vivo.This study underlines the need to consider maternal BMI as a potential confounding factor for cord blood levels of ECFCs in future comparative studies between healthy and pathologic pregnancies.

Published
2013

3. Olive oil polyphenols decrease blood pressure and improve endothelial function in young women with mild hypertension

Author

Alzenira F. Costa, Francisco J. G. Muriana, Pablo Stiefel, Luis Jimenez-Jimenez, María Miranda, Rafael Moreno-Luna, Jose Villar, Antonio J. Vallejo-Vaz, and Rocío Muñoz-Hernández

Subjects
Adult, medicine.medical_specialty, Time Factors, Endothelium, Diastole, Blood Pressure, Hyperemia, Essential hypertension, Severity of Illness Index, chemistry.chemical_compound, Young Adult, Sex Factors, Dietary Fats, Unsaturated, Double-Blind Method, Internal medicine, Internal Medicine, medicine, Humans, Plant Oils, Systole, Olive Oil, Cross-Over Studies, business.industry, Age Factors, Polyphenols, medicine.disease, Crossover study, Surgery, Forearm, Oxidative Stress, medicine.anatomical_structure, Blood pressure, Endocrinology, Treatment Outcome, chemistry, Spain, Hypertension, Female, Endothelium, Vascular, Inflammation Mediators, Asymmetric dimethylarginine, business, Biomarkers, Lipoprotein
Abstract

BACKGROUND Olive oil polyphenols have been associated with several cardiovascular health benefits. This study aims to examine the influence of a polyphenol-rich olive oil on blood pressure (BP) and endothelial function in 24 young women with high-normal BP or stage 1 essential hypertension. METHODS We conducted a double-blind, randomized, crossover dietary-intervention study. After a run-in period of 4 months (baseline values), two diets were used, one with polyphenol-rich olive oil (∼30 mg/day), the other with polyphenol-free olive oil. Each dietary period lasted 2 months with a 4-week washout between diets. Systolic and diastolic BP, serum or plasma biomarkers of endothelial function, oxidative stress, and inflammation, and ischemia-induced hyperemia in the forearm were measured. RESULTS When compared to baseline values, only the polyphenol-rich olive oil diet led to a significant (P < 0.01) decrease of 7.91 mm Hg in systolic and 6.65 mm Hg of diastolic BP. A similar finding was found for serum asymmetric dimethylarginine (ADMA) (-0.09 ± 0.01 µmol/l, P < 0.01), oxidized low-density lipoprotein (ox-LDL) (-28.2 ± 28.5 µg/l, P < 0.01), and plasma C-reactive protein (CRP) (-1.9 ± 1.3 mg/l, P < 0.001). The polyphenol-rich olive oil diet also elicited an increase in plasma nitrites/nitrates (+4.7 ± 6.6 µmol/l, P < 0.001) and hyperemic area after ischemia (+345 ± 386 perfusion units (PU)/sec, P < 0.001). CONCLUSIONS We concluded that the consumption of a diet containing polyphenol-rich olive oil can decrease BP and improve endothelial function in young women with high-normal BP or stage 1 essential hypertension.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results